|
US543153A
(en)
|
|
1895-07-23 |
|
kidder |
|
US4444878A
(en)
|
1981-12-21 |
1984-04-24 |
Boston Biomedical Research Institute, Inc. |
Bispecific antibody determinants
|
|
US5229272A
(en)
|
1989-04-25 |
1993-07-20 |
Igen, Inc. |
Catalytic antibody components
|
|
US5156965A
(en)
|
1983-11-29 |
1992-10-20 |
Igen, Inc. |
Catalytic antibodies
|
|
US5030717A
(en)
|
1986-09-17 |
1991-07-09 |
Scripps Clinic And Research Foundation |
Antibodies which catalyze hydrolysis of ester bonds
|
|
US5126258A
(en)
|
1984-09-07 |
1992-06-30 |
Scripps Clinic And Research Foundation |
Molecules with antibody combining sites that exhibit catalytic properties
|
|
US5436153A
(en)
|
1992-12-02 |
1995-07-25 |
Sprecher; Cindy A. |
Human amyloid protein precursor homolog and Kunitz-type inhibitor
|
|
IL107831A0
(en)
|
1992-12-02 |
1994-05-30 |
Zymogenetics Inc |
Novel human amyloid protein precursor homolog and kunitz-type inhibitor
|
|
CA2161114A1
(en)
|
1993-04-23 |
1994-11-10 |
Andrew D. Napper |
Catalytic antibodies which hydrolyze primary amides and methods for eliciting such antibodies
|
|
US5602021A
(en)
|
1994-12-29 |
1997-02-11 |
Catalytic Antibodies, Inc. |
Method for generating proteolytic enzymes specific against a selected peptide sequence
|
|
US5585108A
(en)
|
1994-12-30 |
1996-12-17 |
Nanosystems L.L.C. |
Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US6261554B1
(en)
|
1995-07-25 |
2001-07-17 |
Introgene B.V. |
Compositions for targeted gene delivery
|
|
US6265389B1
(en)
|
1995-08-31 |
2001-07-24 |
Alkermes Controlled Therapeutics, Inc. |
Microencapsulation and sustained release of oligonucleotides
|
|
US5858351A
(en)
|
1996-01-18 |
1999-01-12 |
Avigen, Inc. |
Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
|
|
US5962313A
(en)
|
1996-01-18 |
1999-10-05 |
Avigen, Inc. |
Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme
|
|
ES2191827T3
(es)
|
1996-10-17 |
2003-09-16 |
Immunomedics Inc |
Conjugado de toxina no antigenica y proteina de fusion de un sistema receptor de penetracion intracelular.
|
|
JP2002511857A
(ja)
|
1997-06-11 |
2002-04-16 |
ザ スクール オブ ファーマシー ユニヴァーシティ オブ ロンドン |
抗体−酵素複合体をプロドラッグと組合せて含む薬学的組成物
|
|
IT1293511B1
(it)
|
1997-07-30 |
1999-03-01 |
Gentili Ist Spa |
Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati
|
|
US6703488B1
(en)
|
1998-01-15 |
2004-03-09 |
Center For Molecular Medicine And Immunology |
Antibody/receptor targeting moiety for enhanced delivery of armed ligand
|
|
US6855804B2
(en)
|
1998-03-23 |
2005-02-15 |
Board Of Regents, The University Of Texas System |
Covalently reactive transition state analogs and methods of use thereof
|
|
DK1068238T3
(da)
|
1998-04-02 |
2013-01-14 |
Xintela Ab |
Integrinheterodimer og subunit deraf
|
|
US7223556B1
(en)
|
1998-10-09 |
2007-05-29 |
President And Fellows Of Harvard College |
Targeted proteolysis by recruitment to ubiquitin protein ligases
|
|
US20020095135A1
(en)
|
2000-06-19 |
2002-07-18 |
David Meeker |
Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
|
|
US20040204379A1
(en)
|
2000-06-19 |
2004-10-14 |
Cheng Seng H. |
Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
|
|
AU2001295041A1
(en)
|
2000-09-08 |
2002-03-22 |
California Institute Of Technology |
Proteolysis targeting chimeric pharmaceutical
|
|
US6649138B2
(en)
|
2000-10-13 |
2003-11-18 |
Quantum Dot Corporation |
Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media
|
|
US7105348B2
(en)
|
2000-10-31 |
2006-09-12 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
US7431923B2
(en)
|
2005-01-03 |
2008-10-07 |
Arius Research Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD63
|
|
US7442777B2
(en)
|
2000-11-29 |
2008-10-28 |
Arius Research Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD63
|
|
US20060210474A1
(en)
|
2000-11-29 |
2006-09-21 |
Young David S |
Cytotoxicity mediation of cells evidencing surface expression of CD63
|
|
US7534429B2
(en)
|
2000-11-29 |
2009-05-19 |
Hoffmann-La Roche Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD63
|
|
US7560424B2
(en)
|
2001-04-30 |
2009-07-14 |
Zystor Therapeutics, Inc. |
Targeted therapeutic proteins
|
|
US20050003014A1
(en)
|
2001-12-21 |
2005-01-06 |
Ketelson Howard Allen |
Use of synthetic inorganic nanoparticles as carriers for ophthalmic and otic drugs
|
|
WO2003057179A2
(en)
|
2002-01-11 |
2003-07-17 |
Biomarin Pharmaceutical, Inc. |
Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
|
|
US7858367B2
(en)
|
2002-04-30 |
2010-12-28 |
Duke University |
Viral vectors and methods for producing and using the same
|
|
WO2004023973A2
(en)
|
2002-09-12 |
2004-03-25 |
Incyte Corporation |
Molecules for diagnostics and therapeutics
|
|
US20050142141A1
(en)
|
2002-11-27 |
2005-06-30 |
Pardridge William M. |
Delivery of enzymes to the brain
|
|
PT1587923E
(pt)
|
2003-01-22 |
2011-12-07 |
Univ Duke |
Construções melhoradas para a expressão de polipéptidos lisossomais
|
|
SE0301087D0
(sv)
|
2003-04-14 |
2003-04-14 |
Cartela Ab |
New monoclonal antibody
|
|
JP4979067B2
(ja)
|
2003-05-01 |
2012-07-18 |
ジェンザイム・コーポレーション |
神経代謝性疾患についての遺伝子治療
|
|
US20040258666A1
(en)
|
2003-05-01 |
2004-12-23 |
Passini Marco A. |
Gene therapy for neurometabolic disorders
|
|
EP1633865B1
(en)
|
2003-06-18 |
2011-09-28 |
Bayer Pharma Aktiengesellschaft |
New biological entities and the use thereof
|
|
US7371539B2
(en)
|
2003-12-03 |
2008-05-13 |
President And Fellows Of Harvard College |
Targeted polypeptide degradation
|
|
US20080014188A1
(en)
|
2004-02-06 |
2008-01-17 |
Zankel Todd C |
Manufacture of Highly Phosphorylated Lysosomal Enzymes and Uses Thereof
|
|
DE602005020745D1
(de)
|
2004-02-10 |
2010-06-02 |
Zystor Therapeutics Inc |
Saure alpha-glukosidase und fragmente davon
|
|
WO2005077333A2
(en)
|
2004-02-10 |
2005-08-25 |
University Of Florida Research Foundation, Inc. |
Gel-based delivery of recombinant adeno-associated virus vectors
|
|
JP2007530538A
(ja)
|
2004-03-25 |
2007-11-01 |
セントカー・インコーポレーテツド |
過剰血管新生と関連する疾患の処置のためのｅｍｍｐｒｉｎアンタゴニストの使用
|
|
US20060171926A1
(en)
|
2004-04-30 |
2006-08-03 |
Passini Marco A |
Gene therapy for neurometabolic disorders
|
|
EP1828390B1
(en)
|
2004-12-15 |
2012-06-13 |
The University Of North Carolina At Chapel Hill |
Chimeric vectors
|
|
JP5137814B2
(ja)
|
2005-04-06 |
2013-02-06 |
ジェンザイム・コーポレーション |
治療ターゲティングのための酸不安定リンカーを介するｐｅｇおよびポリシアルリソソーム酵素のコンジュゲート
|
|
AU2006243776A1
(en)
|
2005-05-02 |
2006-11-09 |
Genzyme Corporation |
Gene therapy for neurometabolic disorders
|
|
CA2611985C
(en)
|
2005-06-17 |
2016-08-16 |
The University Of North Carolina At Chapel Hill |
Nanoparticle fabrication methods, systems, and materials
|
|
PL2578685T3
(pl)
|
2005-08-23 |
2020-01-31 |
The Trustees Of The University Of Pennsylvania |
Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
|
|
CN105709237A
(zh)
|
2005-12-16 |
2016-06-29 |
Ibc 医药公司 |
基于免疫球蛋白的多价生物活性装配体
|
|
CA2641070C
(en)
|
2006-02-06 |
2017-01-03 |
Ramot At Tel-Aviv University Ltd. |
Enzyme replacement therapy for treating lysosomal storage diseases
|
|
ATE537190T1
(de)
|
2006-06-02 |
2011-12-15 |
Regeneron Pharma |
Hochaffine antikörper gegen den humanen il-6- rezeptor
|
|
US20080089891A1
(en)
|
2006-07-26 |
2008-04-17 |
Arius Research, Inc. |
Cancerous disease modifying antibodies
|
|
GB0615662D0
(en)
|
2006-08-07 |
2006-09-13 |
Affitech As |
Antibody
|
|
CA2661023C
(en)
|
2006-08-18 |
2017-08-15 |
Novartis Ag |
Prlr-specific antibody and uses thereof
|
|
AU2007322123A1
(en)
|
2006-11-13 |
2008-05-29 |
Biomarin Pharmaceutical Inc. |
Methods for treating Pompe disease
|
|
US20120322861A1
(en)
|
2007-02-23 |
2012-12-20 |
Barry John Byrne |
Compositions and Methods for Treating Diseases
|
|
WO2008103993A2
(en)
|
2007-02-23 |
2008-08-28 |
University Of Florida Research Foundation, Inc. |
Compositions and methods for treating glycogen storage diseases
|
|
US8569032B2
(en)
|
2007-05-18 |
2013-10-29 |
Tokyo Metropolitan Institute Of Medical Science |
Proteins having acquired A-galactosidase activity
|
|
CA3184105A1
(en)
|
2007-07-27 |
2009-02-05 |
Armagen Inc. |
Methods and compositions for increasing alpha-l-iduronidase activity in the cns
|
|
WO2009075815A1
(en)
|
2007-12-07 |
2009-06-18 |
Duke University |
Immunomodulating gene therapy
|
|
WO2009094561A1
(en)
|
2008-01-24 |
2009-07-30 |
The Government Of The United States Of America As Represented By The Secretary Of The Departmentof |
Induced internalization of surface receptors
|
|
US9617548B2
(en)
|
2008-04-22 |
2017-04-11 |
Vib Vzw |
Liver-specific nucleic acid regulatory elements and methods and use thereof
|
|
WO2009137721A2
(en)
|
2008-05-07 |
2009-11-12 |
Zystor Therapeutics, Inc. |
Lysosomal targeting peptides and uses thereof
|
|
WO2010036460A2
(en)
|
2008-09-29 |
2010-04-01 |
Centocor Ortho Biotech Inc. |
Anti-cd147 antibodies, methods, and uses
|
|
JP2012504961A
(ja)
*
|
2008-10-06 |
2012-03-01 |
ミネルバ バイオテクノロジーズ コーポレーション |
Ｍｕｃ１＊抗体
|
|
EP2241576A1
(en)
|
2009-04-17 |
2010-10-20 |
Trion Pharma Gmbh |
Use of trifunctional bispecific antibodies for the treatment of tumors associated with CD133+/EpCAM+ cancer stem cells
|
|
US8785168B2
(en)
|
2009-06-17 |
2014-07-22 |
Biomarin Pharmaceutical Inc. |
Formulations for lysosomal enzymes
|
|
TWI507525B
(zh)
|
2009-06-26 |
2015-11-11 |
Regeneron Pharma |
具天然免疫球蛋白形式之易分離的雙專一性抗體
|
|
EP2449569B1
(en)
|
2009-07-01 |
2015-08-26 |
Kemet Electronics Corporation |
Multilayer capacitor with high capacitance and high voltage capability
|
|
EA022786B1
(ru)
|
2009-07-31 |
2016-03-31 |
Этрис Гмбх |
Рнк с комбинацией из немодифицированных и модифицированных нуклеотидов для экспрессии белков
|
|
WO2011029823A1
(en)
|
2009-09-09 |
2011-03-17 |
Novartis Ag |
Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
|
|
EP2332995A1
(en)
|
2009-12-10 |
2011-06-15 |
Bayer Schering Pharma Aktiengesellschaft |
Neutralizing prolactin receptor antibodies and their therapeutic use
|
|
WO2011112566A2
(en)
|
2010-03-11 |
2011-09-15 |
Abbott Laboratories |
Basigin binding proteins
|
|
WO2011140279A1
(en)
|
2010-05-04 |
2011-11-10 |
Wayne State University |
Aav-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells
|
|
US8809282B2
(en)
|
2010-05-06 |
2014-08-19 |
Duke University |
Method of reducing titers of antibodies specific for a therapeutic agent
|
|
BR112013007616B1
(pt)
|
2010-09-29 |
2023-01-24 |
Oxyrane Uk Limited |
Métodos para retirar o cap ("uncapping") de porções de manose-1- fosfo-6-manose e desmanosilar n-glicanos fosforilados em uma glicoproteína, para direcionar uma glicoproteína para o interior de uma célula de mamífero, e para converter uma glicoproteína de uma primeira forma que não se liga substancialmente a um receptor de manose-6-fosfato em uma segunda forma que se liga substancialmente a um receptor de manose-6-fosfato em uma célula de mamífero
|
|
US8679478B2
(en)
|
2010-10-04 |
2014-03-25 |
Duke University |
Methods of lysosomal storage disease therapy
|
|
WO2012051220A1
(en)
|
2010-10-11 |
2012-04-19 |
Wichita State University |
Composite magnetic nanoparticle drug delivery system
|
|
HRP20181315T1
(hr)
|
2010-11-22 |
2018-10-19 |
Amicus Therapeutics, Inc. |
Nove signalne sekvence za poboljšanje ekspresije proteina i izlučivanja rekombinantnih enzima i drugih proteina
|
|
CN103443125B
(zh)
|
2010-11-30 |
2019-05-03 |
霍夫曼-拉罗奇有限公司 |
低亲和力血脑屏障受体抗体及其用途
|
|
CN105861548B
(zh)
|
2011-02-25 |
2020-01-10 |
瑞泽恩制药公司 |
Adam6小鼠
|
|
EP2687597B1
(en)
|
2011-03-16 |
2018-12-26 |
Amano Enzyme Inc. |
Modified alpha-glucosidase and applications of same
|
|
WO2012125987A2
(en)
|
2011-03-17 |
2012-09-20 |
Massachusetts Institute Of Technology |
Delivery system
|
|
ES2745470T3
(es)
|
2011-03-31 |
2020-03-02 |
Univ Iowa Res Found |
Partícula de AAV2 que comprende una proteína de la cápside de AAV2 y un vector que comprende un ácido nucleico que codifica una tripeptidilo peptidasa 1 (TPP1) para el tratamiento de lipofuscinosis ceroide infantil tardía (LINCL) en un mamífero no roedor mediante inyección intraventricular o administración icv
|
|
WO2012136519A1
(en)
|
2011-04-06 |
2012-10-11 |
Bayer Pharma Aktiengesellschaft |
Use of neutralizing prolactin receptor antibodies for the treatment and prevention of antiestrogen-resistant breast cancer
|
|
SG10201605874TA
(en)
|
2011-04-22 |
2016-09-29 |
Genzyme Corp |
Modified acid alpha glucosidase with accelerated processing
|
|
US20120283503A1
(en)
|
2011-04-29 |
2012-11-08 |
The Johns Hopkins University |
Nanoparticle loaded stem cells and their use in mri guided hyperthermia
|
|
LT2714752T
(lt)
|
2011-05-27 |
2018-03-12 |
Amicus Therapeutics, Inc. |
Nukreipiančių peptidų kopuliavimo ant rekombinantinių lizosominių fermentų būdai, skirti lizosominio kaupimo ligų gydymo pagerinimui
|
|
EP2530089A1
(en)
|
2011-06-03 |
2012-12-05 |
Bayer Pharma Aktiengesellschaft |
Neutralising prolactin receptor antibody Mat3 and its therapeutical use
|
|
HK1202877A1
(en)
|
2011-11-23 |
2015-10-09 |
伊格尼卡生物治疗公司 |
Anti-cd98 antibodies and methods of use thereof
|
|
US8486399B2
(en)
|
2011-12-02 |
2013-07-16 |
Armagen Technologies, Inc. |
Methods and compositions for increasing arylsulfatase A activity in the CNS
|
|
SMT201900296T1
(it)
|
2011-12-20 |
2019-07-11 |
Regeneron Pharma |
Topi di catena leggera umanizzata
|
|
SG10201704846VA
(en)
|
2012-03-14 |
2017-07-28 |
Regeneron Pharma |
Multispecific antigen-binding molecules and uses thereof
|
|
EP4124346A3
(en)
|
2012-06-19 |
2023-04-19 |
University of Florida Research Foundation, Inc. |
Compositions and methods for treating diseases
|
|
HUE051612T2
(hu)
|
2012-07-11 |
2021-03-01 |
Sangamo Therapeutics Inc |
Eljárások és készítmények lizoszomális tárolási betegségek kezelésére
|
|
MX367126B
(es)
|
2012-08-29 |
2019-08-06 |
Hoffmann La Roche |
Transporte para atravesar la barrera hematoencefálica.
|
|
US8883979B2
(en)
|
2012-08-31 |
2014-11-11 |
Bayer Healthcare Llc |
Anti-prolactin receptor antibody formulations
|
|
ES2679374T3
(es)
|
2012-11-27 |
2018-08-24 |
Biomarin Pharmaceutical Inc. |
Proteínas de fusión terapéuticas dirigidas de enzima lisosómica y usos de las mismas
|
|
JP2016514096A
(ja)
|
2013-02-20 |
2016-05-19 |
バレリオン セラピューティクス， エルエルシー |
ポンぺ病の処置のための方法および組成物
|
|
WO2014130722A1
(en)
|
2013-02-20 |
2014-08-28 |
Valerion Therapeutics, Llc |
Methods and compositions for treatment of forbes-cori disease
|
|
UY35460A
(es)
|
2013-03-15 |
2014-10-31 |
Bayer Healthcare Llc |
Formulaciones de anticuerpos anti-receptor de prolactina
|
|
JP2016523835A
(ja)
|
2013-05-15 |
2016-08-12 |
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ |
中枢神経系へのアデノ随伴ウイルスを介した遺伝子導入
|
|
US9738717B2
(en)
|
2013-05-15 |
2017-08-22 |
The Translational Genomics Research Institute |
Hybridoma clones, monoclonal antibodies, and methods of use
|
|
SG11201509566RA
(en)
|
2013-05-20 |
2015-12-30 |
Genentech Inc |
Anti-transferrin receptor antibodies and methods of use
|
|
US9388243B2
(en)
|
2013-05-29 |
2016-07-12 |
Samsung Electronics Co., Ltd. |
Method of target membrane protein depletion
|
|
US10906981B2
(en)
|
2013-07-19 |
2021-02-02 |
The Regents Of The University Of California |
Compositions and methods related to structures that cross the blood brain barrier
|
|
RU2664471C2
(ru)
|
2013-07-26 |
2018-08-17 |
Юниверсити Оф Айова Рисерч Фаундейшн |
Способы и композиции для лечения болезней мозга
|
|
US9545451B2
(en)
|
2013-08-21 |
2017-01-17 |
Regeneron Pharmaceuticals, Inc. |
Anti-PRLR antibodies and methods for killing PRLR-expressing cells
|
|
TWI641620B
(zh)
|
2013-08-21 |
2018-11-21 |
再生元醫藥公司 |
抗－ｐｒｌｒ抗體及其用途
|
|
WO2015101586A1
(en)
|
2014-01-03 |
2015-07-09 |
F. Hoffmann-La Roche Ag |
Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
|
|
PL3092251T3
(pl)
|
2014-01-06 |
2021-08-02 |
F. Hoffmann-La Roche Ag |
Jednowartościowe moduły transportera wahadłowego przez barierę krew-mózg
|
|
US9629801B2
(en)
|
2014-01-10 |
2017-04-25 |
Wisconsin Alumni Research Foundation |
Blood-brain barrier targeting antibodies
|
|
AU2015208247B2
(en)
|
2014-01-21 |
2021-05-27 |
Universiteit Gent |
Muscle-specific nucleic acid regulatory elements and methods and use thereof
|
|
JP2017114763A
(ja)
|
2014-03-26 |
2017-06-29 |
第一三共株式会社 |
抗ｃｄ９８抗体−薬物コンジュゲート
|
|
WO2015187596A2
(en)
|
2014-06-02 |
2015-12-10 |
Regeneron Pharmaceuticals, Inc. |
Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses
|
|
KR102496206B1
(ko)
|
2014-06-11 |
2023-02-06 |
몰레큘러 템플레이츠, 인코퍼레이션. |
프로테아제-절단 저항성의 시가 독소 a 서브유닛 작동체 폴리펩티드 및 이를 포함하는 세포-표적화 분자
|
|
WO2016044947A1
(en)
|
2014-09-26 |
2016-03-31 |
Exerkine Corporation |
Exosomes useful to treat lysosomal storage disease
|
|
WO2016065319A1
(en)
|
2014-10-24 |
2016-04-28 |
Shire Human Genetic Therapies, Inc. |
Lysosomal targeting of enzymes, and uses thereof
|
|
CA2967830A1
(en)
|
2014-11-14 |
2016-05-19 |
Ossianix, Inc. |
Tfr selective binding compounds and related methods
|
|
JP6779876B2
(ja)
|
2014-11-19 |
2020-11-04 |
ジェネンテック， インコーポレイテッド |
抗トランスフェリン受容体抗体及びその使用方法
|
|
EP3221361B1
(en)
|
2014-11-19 |
2021-04-21 |
Genentech, Inc. |
Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
|
|
MA41022A
(fr)
*
|
2014-11-24 |
2017-10-03 |
Shire Human Genetic Therapies |
Ciblage lysosomial et utilisations correspondantes
|
|
SG11201703750XA
(en)
|
2014-12-10 |
2017-06-29 |
Genentech Inc |
Blood brain barrier receptor antibodies and methods of use
|
|
US10538589B2
(en)
|
2015-01-14 |
2020-01-21 |
Armagen Inc. |
Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
|
|
TWI787796B
(zh)
|
2015-05-04 |
2022-12-21 |
美商Ｃｙｔｏｍｘ生物製藥公司 |
抗ｃｄ７１抗體類、可活化之抗ｃｄ７１抗體類及使用彼等之方法
|
|
CA2990785C
(en)
|
2015-06-24 |
2024-11-12 |
Jcr Pharmaceuticals Co., Ltd. |
ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER
|
|
AU2016282334B2
(en)
|
2015-06-24 |
2022-07-21 |
F. Hoffmann-La Roche Ag |
Anti-transferrin receptor antibodies with tailored affinity
|
|
JP6993958B2
(ja)
|
2015-07-06 |
2022-02-04 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
多重特異性抗原結合分子およびその使用
|
|
HRP20220069T1
(hr)
|
2015-08-10 |
2022-04-15 |
Osaka University |
Antitijelo
|
|
AU2016332900C1
(en)
|
2015-09-29 |
2024-07-04 |
Amgen Inc. |
ASGR inhibitors
|
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
|
MX2018003822A
(es)
|
2015-10-02 |
2018-06-22 |
Hoffmann La Roche |
Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso.
|
|
AU2016341428B2
(en)
|
2015-10-23 |
2021-12-02 |
University Of Iowa Research Foundation |
Methods for treating neurodegenerative diseases using gene therapy to delay disease onset and progression while providing cognitive protection
|
|
MY207684A
(en)
|
2015-12-08 |
2025-03-12 |
Regeneron Pharma |
Compositions and methods for internalizing enzymes
|
|
US10233252B2
(en)
|
2015-12-21 |
2019-03-19 |
Wisconsin Alumni Research Foundation |
pH-dependent antibodies targeting the transferrin receptor and methods of use thereof to deliver a therapeutic agent
|
|
IL299470B2
(en)
|
2015-12-30 |
2026-05-01 |
Amicus Therapeutics Inc |
Improved acid alpha-glucosidase for the treatment of Pompe disease
|
|
AR107483A1
(es)
|
2016-01-29 |
2018-05-02 |
Hanmi Pharm Ind Co Ltd |
Conjugado de enzimas terapéuticas
|
|
KR20180104148A
(ko)
*
|
2016-02-05 |
2018-09-19 |
젠맵 에이/에스 |
개선된 내재화 특징을 갖는 다중특이적 항원-결합 분자
|
|
KR102618519B1
(ko)
|
2016-03-30 |
2023-12-28 |
아미쿠스 세라퓨틱스, 인코포레이티드 |
재조합 산 알파-글루코시다제를 포함하는 제형
|
|
WO2017190079A1
(en)
|
2016-04-28 |
2017-11-02 |
Regeneron Pharmaceuticals, Inc. |
Methods of making multispecific antigen-binding molecules
|
|
CN105820250B
(zh)
|
2016-04-29 |
2019-04-30 |
中国人民解放军第四军医大学 |
一种抗basigin人源化抗体及其应用
|
|
WO2017191274A2
(en)
|
2016-05-04 |
2017-11-09 |
Curevac Ag |
Rna encoding a therapeutic protein
|
|
WO2017214456A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
|
MX2018015272A
(es)
|
2016-06-08 |
2019-08-12 |
Abbvie Inc |
Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
|
|
MX2018015268A
(es)
|
2016-06-08 |
2019-08-12 |
Abbvie Inc |
Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
|
|
CA3033082A1
(en)
|
2016-08-06 |
2018-02-15 |
Ossianix, Inc. |
In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use
|
|
EP3293203A1
(en)
|
2016-09-12 |
2018-03-14 |
Genethon |
Acid-alpha glucosidase variants and uses thereof
|
|
EP3293259A1
(en)
|
2016-09-12 |
2018-03-14 |
Genethon |
Acid-alpha glucosidase variants and uses thereof
|
|
KR102617502B1
(ko)
|
2016-09-12 |
2023-12-26 |
제네똥 |
산-알파 글루코시다제 변이체 및 이의 용도
|
|
US20190269797A1
(en)
|
2016-11-04 |
2019-09-05 |
The Children's Hospital Of Philadelphia |
Gene transfer compositions, methods and uses for treating neurodegenerative diseases
|
|
MX2019006131A
(es)
|
2016-11-29 |
2019-08-21 |
Regeneron Pharma |
Metodos para tratar cancer de mama positivo para prlr.
|
|
TWI833178B
(zh)
|
2016-12-26 |
2024-02-21 |
日商Ｊｃｒ製藥股份有限公司 |
通過血腦障壁之新穎抗人類運鐵蛋白受體抗體
|
|
KR102580320B1
(ko)
|
2017-01-27 |
2023-09-19 |
신텔라 에이비 |
골 및 연골 손상 또는 질환의 예방 및 치료
|
|
JP2020511130A
(ja)
|
2017-03-09 |
2020-04-16 |
サイトメックス セラピューティクス インコーポレイテッド |
Ｃｄ１４７抗体、活性化可能ｃｄ１４７抗体、ならびにその作製および使用の方法
|
|
CN119113091A
(zh)
|
2017-05-15 |
2024-12-13 |
阿米库斯治疗学公司 |
重组人类酸性α-葡萄糖苷酶
|
|
WO2018210898A1
(en)
|
2017-05-18 |
2018-11-22 |
F. Hoffmann-La Roche Ag |
Reduction of application-related side reaction of a therapeutic antibody
|
|
AU2018281280B2
(en)
*
|
2017-06-07 |
2024-12-19 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for internalizing enzymes
|
|
PE20200481A1
(es)
|
2017-07-10 |
2020-03-03 |
Bayer Pharma AG |
Anticuerpo del receptor de prolactina para la perdida de cabello con patrones masculinos y femeninos
|
|
DK3684423T5
(da)
|
2017-09-20 |
2024-08-26 |
4D Molecular Therapeutics Inc |
Adeno-associerede virusvariantcapsider og fremgangsmåder til anvendelse deraf
|
|
PE20210125A1
(es)
|
2017-10-14 |
2021-01-19 |
Abbvie Inc |
Conjugados de farmaco-anticuerpo activable anti-cd71 y metodos de uso de estos
|
|
CN111683972A
(zh)
|
2018-02-05 |
2020-09-18 |
Jcr制药股份有限公司 |
用于将药剂递送至肌肉的方法
|
|
CN111936621B
(zh)
|
2018-02-05 |
2025-05-13 |
奥登茨治疗公司 |
转录调控元件和它的用途
|
|
CN112040985A
(zh)
|
2018-02-07 |
2020-12-04 |
瑞泽恩制药公司 |
用于递送治疗性蛋白质的方法和组合物
|
|
JP2021518840A
(ja)
|
2018-03-15 |
2021-08-05 |
バレリオン セラピューティクス， エルエルシー |
ポリグルコサン障害の処置のための方法及び組成物
|
|
EP3552631A1
(en)
|
2018-04-10 |
2019-10-16 |
Inatherys |
Antibody-drug conjugates and their uses for the treatment of cancer
|
|
SG11202011191WA
(en)
|
2018-05-16 |
2020-12-30 |
Spark Therapeutics Inc |
Codon-optimized acid αlpha-glucosidase expression cassettes and methods of using same
|
|
EP3793591A1
(en)
|
2018-05-17 |
2021-03-24 |
Regeneron Pharmaceuticals, Inc. |
Anti-cd63 antibodies, conjugates, and uses thereof
|
|
WO2020023390A1
(en)
|
2018-07-25 |
2020-01-30 |
Modernatx, Inc. |
Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
|
|
EP3830127A4
(en)
|
2018-08-02 |
2022-06-29 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating pompe disease
|
|
CN113226352B
(zh)
|
2018-08-24 |
2025-08-26 |
星火治疗有限公司 |
最优化启动子序列、无内含子的表达结构及使用方法
|
|
WO2020102645A1
(en)
|
2018-11-16 |
2020-05-22 |
Asklepios Biopharmaceutical, Inc. |
Therapeutic adeno-associated virus for treating pompe disease
|
|
BR112021009913A2
(pt)
|
2018-12-05 |
2021-08-17 |
Abeona Therapeutics, Inc. |
vetor viral adeno-associado recombinante para inserção gênica
|
|
EP3908608A1
(en)
|
2019-01-09 |
2021-11-17 |
Vect-Horus |
Transferrin receptor-binding molecules, conjugates thereof and their uses
|
|
WO2020163480A1
(en)
|
2019-02-05 |
2020-08-13 |
Amicus Therapeutics, Inc. |
Recombinant human acid alpha-glucosidase and uses thereof
|
|
US20220193261A1
(en)
|
2019-04-30 |
2022-06-23 |
The Trustees Of The University Of Pennsylvania |
Compositions useful for treatment of pompe disease
|
|
EP3996696A1
(en)
|
2019-07-09 |
2022-05-18 |
Genethon |
Treatment of glycogen storage disease (gsd)
|
|
TW202346348A
(zh)
|
2022-01-10 |
2023-12-01 |
美商再生元醫藥公司 |
作為基因治療所遞送之bbb靶向的gaa在龐貝氏症小鼠模型中治療cns及肌肉
|